Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
Rhea-AI Summary
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has scheduled the release of its full year and fourth quarter 2024 financial results for Monday, March 10, 2025, before U.S. financial markets open. The commercial stage specialty pharmaceutical company will follow the release with a management-hosted conference call and webcast to discuss financial and business results.
Interested parties can access the live webcast through the company's website at www.fennecpharma.com under the Investors & Media section's News & Events/Event Calendar page. Participants are advised to connect at least 15 minutes before the conference call to allow time for any necessary software downloads. A replay of the webcast will be available on the company's website for thirty days following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FENC gained 1.03%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2024 financial results before the opening of the U.S. financial markets on Monday, March 10, 2025. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
Conference Call & Webcast Detail:
| Date: | Monday, March 10, 2025 |
| Time: | 8:30 a.m. Eastern Time |
| Link: | https://edge.media-server.com/mmc/p/7bafbd7q |
To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When will Fennec Pharmaceuticals (FENC) release Q4 2024 earnings?
How can investors access Fennec Pharmaceuticals' (FENC) Q4 2024 earnings call?
How long will FENC's Q4 2024 earnings call replay be available?
What time should investors join FENC's Q4 2024 earnings call?
